Clonidine Project:

Clonidine Project:

BACKGROUND: Perioperative myocardial ischemia occurs in 20-40% of patients at risk for cardiac morbidity and is associated with a 9-fold increase in risk of perioperative cardiac death, myocardial infarction, or unstable angina, and a 2-fold risk long-term. The alpha-2 agonist Mivazerol has been shown to reduce perioperative cardiac mortality. This randomized, placebo-controlled, double-blinded, trial tested the hypothesis that prophylactic perioperative administration of the alpha 2 agonist clonidine is safe, improves pain control, reduces the incidence and severity of perioperative myocardial ischemia, and finally lowers the risk of long term death,

METHODS: Two-hundred patients with, or at risk for, coronary artery disease were randomized to two study groups (clonidine vs. placebo). Monitoring included a preoperative history and physical examination and daily assessment of adverse events. Twelve-lead electrocardiography (ECG), 3-lead Holter ECG, and creatinine phosphokinase with myocardial banding (CPK with MB) data were collected. Clonidine (0.2 mg P.O. and TTS#2 Patch) or placebo was administered before induction of anesthesia.

RESULTS: Data collection is complete and are being analyzed.

CONCLUSIONS: To be announced.

Atenolol	Clonidine	ECOM
L-Arginine	Warm Cardioplegia

Email: info@cardiacengineering.com

Return to CardiacEngineering.com
State of the Art Quantitative Cardiovascular Research and Design